Marker Therapeutics Inc - ESG Rating & Company Profile powered by AI
Other corporations in the rating industry group for Marker Therapeutics Inc are displayed below. The Sustainability rating for Marker Therapeutics Inc indicates its reporting of the UN Sustainable Development Goals. This ESG rating includes 17 United Nations Sustainable Development Goals including: 'Good Health & Wellbeing', 'Industry, Innovation & Infrastructure' and 'Peace, Justice & Strong Institutions'.
Marker Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.7; made up of an environmental score of 0.0, social score of 0.0 and governance score of 2.0.
0.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1894 | Chongqing Zhifei Biological Products Co Ltd | 0.8 | Low |
| 1894 | Valens Company Inc | 0.8 | Low |
| 1898 | Marker Therapeutics Inc | 0.7 | Low |
| 1898 | CKD Bio Corp | 0.7 | Low |
| 1898 | Australis Capital Inc | 0.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Marker Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Marker Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Marker Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Marker Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Marker Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Marker Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Marker Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Marker Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Marker Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Marker Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Marker Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Marker Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Marker Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Marker Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Marker Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Marker Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Marker Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Marker Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.